New Drug Application For Fostemsavir Submitted To FDA

Infectious Disease Advisor (12/11, Park) reports, “The New Drug Application (NDA) for fostemsavir (ViiV Healthcare), a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection, has been submitted to the Food and Drug Administration (...